Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
Amino Acid Sequence
Angiotensin-Converting Enzyme 2
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Antigens, Viral
/ chemistry
Betacoronavirus
/ genetics
Binding Sites
COVID-19
Coronavirus Infections
/ virology
Cross Reactions
Epitopes
/ immunology
HEK293 Cells
Humans
Neutralization Tests
Pandemics
Peptidyl-Dipeptidase A
/ immunology
Pneumonia, Viral
/ virology
Severe acute respiratory syndrome-related coronavirus
/ genetics
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ chemistry
COVID-19
Cross-neutralization
Neutralizing monoclonal antibodies
Receptor-binding domain
SARS-CoV
SARS-CoV-2
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
04
04
2020
revised:
03
05
2020
accepted:
08
05
2020
pubmed:
15
5
2020
medline:
24
6
2020
entrez:
15
5
2020
Statut:
ppublish
Résumé
SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs.
Identifiants
pubmed: 32405117
doi: 10.1016/j.antiviral.2020.104820
pii: S0166-3542(20)30234-5
pmc: PMC7219369
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, Viral
0
Epitopes
0
Spike Glycoprotein, Coronavirus
0
spike glycoprotein, SARS-CoV
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104820Subventions
Organisme : NIAID NIH HHS
ID : R01 AI137472
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI139092
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no competing interests.
Références
Nat Commun. 2014;5:3067
pubmed: 24473083
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Virol. 2016 Dec 16;91(1):
pubmed: 27795425
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
J Virol. 2006 Jun;80(12):5757-67
pubmed: 16731915
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81
pubmed: 15474494
Lancet. 2020 Mar 21;395(10228):949
pubmed: 32087125
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Vaccine. 2006 Jun 29;24(26):5498-508
pubmed: 16725238
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
Nature. 2020 Mar;579(7799):321
pubmed: 32179860
Lancet. 2003 Oct 25;362(9393):1353-8
pubmed: 14585636
Lancet. 2004 Mar 20;363(9413):938-47
pubmed: 15043961
J Immunol. 2006 May 15;176(10):6085-92
pubmed: 16670317
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
J Immunol. 2005 Apr 15;174(8):4908-15
pubmed: 15814718
Nat Commun. 2016 Nov 22;7:13473
pubmed: 27874853
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651